KUSTE BIOPHARMA owns two JNK inhibitors previously extensively studied, and whose safety and efficacy have been demonstrated in a variety of therapeutic applications.
Our molecules have a strong safety profile, they have proven effects in local delivery and can therefore be used by the urology practitioner to treat BPS/IC.